Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Development of a novel protein-based inhibitor of NF-kB

FY 2023-24

Summary
The NF-kB pathway plays a crucial role in immune defence and inflammatory responses, however, its pro-inflammatory and pro-proliferative characteristics have been identified to be related to persistent infections and chronic inflammation in autoimmunity. Despite current advances in NF-kB inhibitors, crosstalks between signalling pathways have been the obstacle that hinders therapeutic potency and specificity. This study investigates the bacterial effector that directly inhibits the NF-kB heterodimer during host infections (NleC) and uses a toxin-based delivery platform (LCT) to mediate receptor-specific intracellular protein delivery. Previously, we demonstrated that genetic fusions of NleC with LCTs can deliver NleC into intracellular site-of-action and inhibit NF-kB by direct NF-kB cleavage. The proposed experiment aims to explore the immunosuppressive properties of NleC-LCT. By directing NleC-LCT towards naive macrophages, we expect to see a shift in phenotypes away from proinflammatory states upon NF-kB inhibition. Furthermore, efforts are made to retarget LCT platforms to macrophage-specific receptors. The rewiring of LCT's receptor binding domain seeks to enhance macrophage specificity, confirmed through flow cytometry and functional characterization. Additionally, in vivo models such as systemic lupus erythematosus can be used to demonstrate NleC-LCT potential to inhibit proinflammatory cytokine secretion and tissue damage. This study focuses on designing toxin-based molecules, incorporating NleC, to selectively target NF-kB in macrophages. By advancing precise and potent anti-inflammatory therapeutics, the proposal addresses the challenge of systemic toxicity in healthy cells, offering a novel approach for mitigating autoinflammatory diseases.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
505930
Name
Cao Shi Bo
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of a novel protein-based inhibitor of NF-kB
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autoinflammatory Diseases; Intracellular Delivery; Large Clostridial Toxins; Macrophages; Microbial Effectors; Nf-Kb Inhibitor; Nlec; P65 Cleavage; Protein Engineering; Signaling Pathway
Abstract
The NF-kB pathway plays a crucial role in immune defence and inflammatory responses, however, its pro-inflammatory and pro-proliferative characteristics have been identified to be related to persistent infections and chronic inflammation in autoimmunity. Despite current advances in NF-kB inhibitors, crosstalks between signalling pathways have been the obstacle that hinders therapeutic potency and specificity. This study investigates the bacterial effector that directly inhibits the NF-kB heterodimer during host infections (NleC) and uses a toxin-based delivery platform (LCT) to mediate receptor-specific intracellular protein delivery. Previously, we demonstrated that genetic fusions of NleC with LCTs can deliver NleC into intracellular site-of-action and inhibit NF-kB by direct NF-kB cleavage. The proposed experiment aims to explore the immunosuppressive properties of NleC-LCT. By directing NleC-LCT towards naive macrophages, we expect to see a shift in phenotypes away from proinflammatory states upon NF-kB inhibition. Furthermore, efforts are made to retarget LCT platforms to macrophage-specific receptors. The rewiring of LCT's receptor binding domain seeks to enhance macrophage specificity, confirmed through flow cytometry and functional characterization. Additionally, in vivo models such as systemic lupus erythematosus can be used to demonstrate NleC-LCT potential to inhibit proinflammatory cytokine secretion and tissue damage. This study focuses on designing toxin-based molecules, incorporating NleC, to selectively target NF-kB in macrophages. By advancing precise and potent anti-inflammatory therapeutics, the proposal addresses the challenge of systemic toxicity in healthy cells, offering a novel approach for mitigating autoinflammatory diseases.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cao, Shi Bo
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~